CK 0805
Alternative Names: CK-0805Latest Information Update: 01 Sep 2023
At a glance
- Originator Cellenkos
- Class T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Graft-versus-host disease
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Inflammatory bowel diseases in USA (Parenteral) (Cellenkos pipeline, August 2023)
- 11 Oct 2022 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral) (Cellenkos website, October 2022)
- 06 Jul 2021 Preclinical trials in Graft-versus-host disease in USA (Parenteral) before July 2021 (Cellenkos pipeline, July 2021)